AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...
AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...
Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...
AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...
This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...
The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...
Hosted on MSN12d
AstraZeneca Rises Almost 9% in a Month: How to Play the StockAstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
AstraZeneca Pharma India Ltd has received the nod from the Central Drugs Standard Control Organisation (CDSCO) to import and ...
AstraZeneca Pharma India has received approval from CDSCO to import and distribute the cancer treatment drug Durvalumab ...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
AstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback